Literature DB >> 15726858

Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003.

Mariscelle M Sales1, Francesca E Cunningham, Peter A Glassman, Michael A Valentino, Chester B Good.   

Abstract

The Department of Veterans Affairs (VA) Pharmacy Benefits Management Strategic Healthcare Group (VA PBM) oversees the formulary for the entire VA system, which serves more than 4 million veterans and provides more than 108 million prescriptions per year. Since its establishment in 1995, the VA PBM has managed pharmaceuticals and pharmaceutical-related policies, including drug safety and efficacy evaluations, pharmacologic management algorithms, and criteria for drug use. These evidence-based practices promote, optimize, and assist VA providers with the safe and appropriate use of pharmaceuticals while allowing for formulary decisions that can result in substantial cost savings. The VA PBM also has utilized various contracting techniques to standardize generic agents as well as specific drugs and drug classes (eg, antihistamines, angiotensin-converting enzyme inhibitors, alpha-blockers, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [statins]). These methods have enabled the VA to save approximately dollar 1.5 billion since 1996 even as drug expenditures continued to rise from roughly dollar 1 billion in fiscal year (FY) 1996 to more than dollar 3 billion in FY 2003. Furthermore, the VA PBM has established an outcomes research section to undertake quality-improvement and safety initiatives that ultimately monitor and determine the clinical impact of formulary decisions on the VA system nationwide. The experiences of this pharmacy benefits program, including clinical and contracting processes/procedures and their impact on the VA healthcare system, are described.

Mesh:

Substances:

Year:  2005        PMID: 15726858

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  17 in total

1.  The Veterans Health Administration: an American success story?

Authors:  Adam Oliver
Journal:  Milbank Q       Date:  2007       Impact factor: 4.911

2.  Access to affordable medications: the Department of Veterans Affairs pharmacy plan as a national model.

Authors:  Chester B Good; Michael Valentino
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

3.  Does medication adherence following a copayment increase differ by disease burden?

Authors:  Virginia Wang; Chuan-Fen Liu; Christopher L Bryson; Nancy D Sharp; Matthew L Maciejewski
Journal:  Health Serv Res       Date:  2011-06-20       Impact factor: 3.402

4.  Canadian list of essential medications: Potential and uncertainties.

Authors:  Navindra Persaud; Haroon Ahmad
Journal:  Can Fam Physician       Date:  2017-04       Impact factor: 3.275

Review 5.  Patterns of Zolpidem Use in Male and Female Veterans Following Revised FDA Dosing Guidelines.

Authors:  Sabra S Inslicht; Thomas C Neylan
Journal:  J Clin Sleep Med       Date:  2018-07-15       Impact factor: 4.062

6.  Association of income and prescription drug coverage with generic medication use among older adults with hypertension.

Authors:  Alex D Federman; Ethan A Halm; Carolyn Zhu; Tsivia Hochman; Albert L Siu
Journal:  Am J Manag Care       Date:  2006-10       Impact factor: 2.229

7.  Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.

Authors:  Thomas R Radomski; Chester B Good; Carolyn T Thorpe; Xinhua Zhao; Zachary A Marcum; Peter A Glassman; John Lowe; Maria K Mor; Michael J Fine; Walid F Gellad
Journal:  J Manag Care Spec Pharm       Date:  2015-12-14

8.  Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.

Authors:  Grant W Cannon; Ted R Mikuls; Candace L Hayden; Jian Ying; Jeffrey R Curtis; Andreas M Reimold; Liron Caplan; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Brian C Sauer
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

9.  A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.

Authors:  Rajan Ragupathy; Katri Aaltonen; June Tordoff; Pauline Norris; David Reith
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

10.  Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers.

Authors:  Amy C Justice; K A McGinnis; M Skanderson; C C Chang; C L Gibert; M B Goetz; D Rimland; M C Rodriguez-Barradas; K K Oursler; S T Brown; R S Braithwaite; M May; K E Covinsky; M S Roberts; S L Fultz; K J Bryant
Journal:  HIV Med       Date:  2009-09-14       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.